An FDA Form 483 cited unaddressed contamination, pest infestations, and equipment failures at manufacturer’s Bloomington, IN ...

Drugmaker Novo Nordisk received accelerated approval for the drug’s use in people with moderate to advanced liver scarring, ...

Novo Nordisk slashes Wegovy prices by 50% for cash-paying patients amid Trump's pressure on drugmakers to reduce costs.

GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of ...

As appetite-suppressing drugs change the way people eat, businesses are adapting to GLP-1 users by offering smaller portions ...

Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” second-quarter 2025 ...

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

A growing number of patients claim popular weight loss and diabetes drugs like Ozempic can cause a rare but very serious side ...

In its 2025 M&A trends survey, Deloitte found a sense of optimism among respondents, who cited strong performance and ...

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...